CA2555370C - Improved modalities for the treatment of degenerative diseases of the retina - Google Patents

Improved modalities for the treatment of degenerative diseases of the retina Download PDF

Info

Publication number
CA2555370C
CA2555370C CA2555370A CA2555370A CA2555370C CA 2555370 C CA2555370 C CA 2555370C CA 2555370 A CA2555370 A CA 2555370A CA 2555370 A CA2555370 A CA 2555370A CA 2555370 C CA2555370 C CA 2555370C
Authority
CA
Canada
Prior art keywords
cells
human
rpe
suspension
rpe cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2555370A
Other languages
English (en)
French (fr)
Other versions
CA2555370A1 (en
Inventor
Irina V. Klimanskaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Priority to CA2937099A priority Critical patent/CA2937099A1/en
Publication of CA2555370A1 publication Critical patent/CA2555370A1/en
Application granted granted Critical
Publication of CA2555370C publication Critical patent/CA2555370C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
CA2555370A 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina Expired - Lifetime CA2555370C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2937099A CA2937099A1 (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53896404P 2004-01-23 2004-01-23
US60/538,964 2004-01-23
PCT/US2005/002273 WO2005070011A2 (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2937099A Division CA2937099A1 (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina

Publications (2)

Publication Number Publication Date
CA2555370A1 CA2555370A1 (en) 2005-08-04
CA2555370C true CA2555370C (en) 2024-02-06

Family

ID=34807248

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2555370A Expired - Lifetime CA2555370C (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina
CA2937099A Pending CA2937099A1 (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2937099A Pending CA2937099A1 (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina

Country Status (15)

Country Link
US (6) US7736896B2 (https=)
EP (8) EP2929782A1 (https=)
JP (10) JP2007522131A (https=)
KR (3) KR101398356B1 (https=)
CN (3) CN1968608B (https=)
AU (6) AU2005207042B2 (https=)
BR (1) BRPI0507074A (https=)
CA (2) CA2555370C (https=)
ES (1) ES2721174T3 (https=)
HK (2) HK1216068A1 (https=)
IL (3) IL177015B (https=)
MX (4) MX375065B (https=)
NZ (1) NZ548929A (https=)
SG (4) SG188122A1 (https=)
WO (1) WO2005070011A2 (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043614B2 (en) * 2004-03-09 2011-10-25 Ahlfors Jan-Eric W Autogenic living scaffolds and living tissue matrices: methods and uses thereof
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2929782A1 (en) * 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
US7838727B2 (en) 2004-11-04 2010-11-23 Advanced Cell Technology, Inc. Derivation of embryonic stem cells
CN1966080B (zh) * 2005-11-17 2011-06-08 李凌松 一种治疗老年痴呆症、帕金森病的神经干细胞注射液
US7541186B2 (en) * 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
AU2007248412A1 (en) 2006-05-03 2007-11-15 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
EP2128244A4 (en) * 2007-01-18 2012-05-09 Riken PROCESS FOR INDUCTION / DIFFERENTIATION TO A PHOTOREZEPTORZELLE
US8796021B2 (en) 2007-02-23 2014-08-05 Advanced Cell Technology, Inc. Blastomere culture to produce mammalian embryonic stem cells
EP2147094B2 (en) * 2007-04-18 2018-02-21 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
EP2607477B1 (en) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US20090028831A1 (en) * 2007-07-23 2009-01-29 University Of Kentucky Research Foundation Stem cell regulator, compositions and methods of use
DK2209888T3 (da) 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
AU2015201435B2 (en) * 2007-10-12 2017-02-02 Astellas Institute For Regenerative Medicine Improved methods of producing RPE cells and compositions of RPE cells
US8481313B2 (en) * 2008-04-22 2013-07-09 Regenerative Research Foundation Retinal pigment epithelial stem cells
EP2470645B1 (en) 2009-08-24 2019-06-26 Wisconsin Alumni Research Foundation Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same
IL281453B (en) * 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
EP2593117B1 (en) 2010-07-12 2019-03-20 University of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
WO2012012803A2 (en) 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
JP2012231786A (ja) * 2011-04-18 2012-11-29 Kyushu Univ 標的遺伝子の発現変化による食品機能成分及び医薬品感受性評価方法
US10478206B2 (en) 2011-04-29 2019-11-19 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
US9932560B2 (en) 2011-05-13 2018-04-03 Elixirgen, Llc Use of Zscan4 and Zscan4-dependent genes for direct reprogramming of somatic cells
CA2835215C (en) 2011-05-18 2023-10-10 The Regents Of The University Of California Non-immortal human retinal cell compositions, method for preparing them, and their use for treating retinal diseases
WO2013015835A1 (en) 2011-07-22 2013-01-31 Seven Networks, Inc. Mobile application traffic optimization
CN103007355B (zh) * 2011-09-20 2014-08-13 同济大学 一种水凝胶-纳米纤维膜及其制备方法和用途
IL287381B2 (en) 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
ES2700980T3 (es) * 2012-02-17 2019-02-20 Schepens Eye Res Inst Perfil fenotípico de células progenitoras de retina humana
US10519422B2 (en) 2012-02-29 2019-12-31 Riken Method of producing human retinal pigment epithelial cells
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
KR102254082B1 (ko) * 2012-08-24 2021-05-18 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 망막 색소 상피 세포 시트의 제조 방법
EP4292600A3 (en) 2013-03-15 2024-04-10 Astellas Institute for Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
EP2980207B1 (en) * 2013-03-25 2018-12-05 Foundation for Biomedical Research and Innovation at Kobe Cell sorting method
EP2796545A1 (en) * 2013-04-26 2014-10-29 Université Pierre et Marie Curie (Paris 6) Methods for obtaining retinal progenitors, retinal pigmented epithelial cells and neural retinal cells
WO2015080297A1 (en) 2013-11-27 2015-06-04 Kyoto Prefectural Public University Corporation Application of laminin to corneal endothelial cell culture
MX2016007671A (es) 2013-12-11 2016-10-14 Pfizer Ltd Metodo para producir celulas del epitelio pigmentario retiniano.
JP6770435B2 (ja) 2014-10-31 2020-10-14 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
RU2718062C2 (ru) 2014-10-31 2020-03-30 Сэндзю Фармасьютикал Ко., Лтд. Новое лечение роговицы с применением ламинина
SG10201907918VA (en) 2015-03-23 2019-10-30 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
CN108697641A (zh) 2015-08-18 2018-10-23 安斯泰来再生医药协会 临床制剂
SG11201801770VA (en) 2015-09-08 2018-04-27 Sumitomo Dainippon Pharma Co Ltd Method for producing retinal pigment epithelial cells
AU2016318774B2 (en) 2015-09-08 2022-08-18 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
DK3347456T3 (da) 2015-09-08 2024-02-19 Us Health Fremgangsmåde til reproducerbar differentiering af retinale pigmentepitelceller af klinisk kvalitet
US10947502B2 (en) 2015-10-20 2021-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
CN106609255B (zh) * 2015-10-22 2019-11-05 同济大学 含pj34和视网膜色素上皮细胞的细胞悬液及其应用
CN106609263B (zh) * 2015-10-22 2020-04-07 同济大学 高效诱导多能干细胞向视网膜色素上皮细胞分化的方法
CN106609257B (zh) * 2015-10-22 2020-04-10 同济大学 高效分离体外诱导的rpe细胞和rpc的方法
CN106609256B (zh) * 2015-10-22 2020-04-07 同济大学 体外诱导人胚胎干细胞分化为视网膜色素上皮细胞的方法
CN106282096A (zh) * 2016-10-19 2017-01-04 江苏艾尔康生物医药科技有限公司 一种人类视网膜色素上皮细胞层的分离培养方法
WO2018164240A1 (ja) 2017-03-08 2018-09-13 大日本住友製薬株式会社 網膜色素上皮細胞の製造方法
WO2018170494A1 (en) * 2017-03-16 2018-09-20 Bio Time, Inc. Methods for measuring therapeutic effects of retinal disease therapies
SG11201909331UA (en) 2017-04-18 2019-11-28 Fujifilm Cellular Dynamics Inc Antigen-specific immune effector cells
CA3075883A1 (en) * 2017-09-14 2019-03-21 Riken Method for amplifying cone photoreceptors or rod photoreceptors using dorsalization signal transmitter or ventralization signal transmitter
MX2020005033A (es) * 2017-11-15 2020-10-28 Friedrich Miescher Institute For Biomedical Res Promotor especifico de las celulas del epitelio pigmentario retinal en primates.
CN108029638B (zh) * 2017-12-04 2020-04-21 四川省人民医院 一种视网膜色素变性疾病动物模型的构建方法及应用
US11946069B2 (en) 2018-03-12 2024-04-02 RxCell, Inc. Method for generating multiple cellular products from single pluripotent cell source
JP7553924B2 (ja) * 2019-04-26 2024-09-19 国立研究開発法人理化学研究所 神経網膜と網膜色素上皮細胞とハイドロゲルとを含む複合体及びその製造方法
TW202130806A (zh) 2019-10-30 2021-08-16 安斯泰來再生醫藥協會 用於產生視網膜色素上皮細胞之方法
RU2730937C1 (ru) * 2019-11-01 2020-08-26 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Миндрава России) Способ трансплантации клеток ретинального пигментного эпителия (РПЭ), дифференцированных из индуцированных плюрипотентных стволовых клеток человека, при атрофии ретинального пигментного эпителия
JPWO2022191216A1 (https=) 2021-03-09 2022-09-15
EP4428227A4 (en) 2021-11-19 2025-11-12 Riken PROCESS FOR PRODUCING LEAF-SHAPED RETINAL TISSUE
CN118871141A (zh) 2022-03-16 2024-10-29 住友制药株式会社 移植用介质
WO2023201361A1 (en) 2022-04-15 2023-10-19 Aspen Neuroscience, Inc. Methods of classifying the differentiation state of cells and related compositions of differentiated cells
EP4659755A1 (en) 2023-02-14 2025-12-10 RACTHERA Co., Ltd. Therapeutic drug for retinal pigment epithelium tears
JPWO2024204596A1 (https=) 2023-03-29 2024-10-03

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69329556D1 (de) 1993-04-30 2000-11-16 Photogenesis Inc Transplantation des retinalen pigmentepithels
US6878544B2 (en) 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
CA2277278A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US6331406B1 (en) * 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
EP1044024A1 (en) 1998-01-02 2000-10-18 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
WO1999045094A1 (en) 1998-03-02 1999-09-10 Compucyte Corp. Selective cell analysis
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
MXPA02004233A (es) 1999-10-28 2004-02-17 Univ Massachusetts Produccion ginogenetica o androgenetica de celulas pluripotentes y lineas celulares, y uso de las mismas para producir celulas diferenciadas y tejidos.
JP3454206B2 (ja) * 1999-11-10 2003-10-06 三菱電機株式会社 雑音抑圧装置及び雑音抑圧方法
AU2927501A (en) * 2000-01-07 2001-07-24 Oregon Health And Science University Clonal propagation of primate offspring by embryo splitting
US6602711B1 (en) * 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
CA2456008A1 (en) 2000-08-19 2002-02-28 Axordia Limited Stem cell differentiation
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
EP1339438B1 (en) 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
DE10108412B4 (de) * 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
EP1393066A4 (en) 2001-05-15 2006-01-25 Rappaport Family Inst For Res INSULIN-PRODUCING CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS
WO2003006950A2 (en) 2001-07-12 2003-01-23 Geron Corporation Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
MXPA04005010A (es) * 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
ATE526041T1 (de) 2001-12-11 2011-10-15 Fibrogen Inc Verfahren zur hemmung okularer vorgänge
EP1495120B1 (en) 2002-04-18 2012-10-10 Acuity Pharmaceuticals, Inc Means and methods for the specific modulation of target genes in the eye
US7422736B2 (en) 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
CN1720055A (zh) * 2002-10-04 2006-01-11 组织技术公司 视网膜上皮细胞在羊膜上的培养和移植
WO2004034734A1 (ja) * 2002-10-08 2004-04-22 Nec Corporation アレイ装置および携帯端末
EP1565107A4 (en) * 2002-11-14 2008-03-05 Ethicon Endo Surgery Inc METHOD AND DEVICES FOR DETECTING TISSUE CELLS
CA2518677A1 (en) * 2003-03-03 2004-12-09 Nagaoka & Co., Ltd. Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
EP2929782A1 (en) 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) * 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
US7838727B2 (en) 2004-11-04 2010-11-23 Advanced Cell Technology, Inc. Derivation of embryonic stem cells
CN101155913B (zh) 2005-02-11 2011-07-06 新加坡科技研究局 增殖干细胞的方法
KR100832592B1 (ko) 2006-08-17 2008-05-27 박현숙 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법
EP2147094B2 (en) * 2007-04-18 2018-02-21 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
DK2209888T3 (da) 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
HU0700675D0 (en) 2007-10-15 2007-12-28 Mta Tamogatott Kutatohelyek Ir Method for monitoring stem cell differentiation
US20090233324A1 (en) * 2008-03-11 2009-09-17 Kopf-Sill Anne R Methods for Diagnosing Cancer Using Samples Collected From A Central Vein Location or an Arterial Location
US8652123B2 (en) * 2008-09-02 2014-02-18 Geoffrey C. GURTNER Methods and devices for improving the appearance of tissue
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
WO2012012803A2 (en) * 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
ES2722207T3 (es) 2011-04-29 2019-08-08 Univ Southern California Procedimientos para la crioconservación de células epiteliales de pigmento retiniano derivadas de citoblastos crecidas sobre un sustrato polimérico
IL287381B2 (en) 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
US9458428B2 (en) 2012-06-05 2016-10-04 The Regents Of The University Of California Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells

Also Published As

Publication number Publication date
US7736896B2 (en) 2010-06-15
JP2016195862A (ja) 2016-11-24
SG10201912182UA (en) 2020-02-27
EP2438815A3 (en) 2012-10-03
EP4269561A3 (en) 2024-01-03
HK1162931A1 (en) 2012-09-07
AU2010249263A1 (en) 2011-01-06
AU2013201791A1 (en) 2013-04-11
IL291162A (en) 2022-05-01
AU2013201791B2 (en) 2016-08-18
JP2007522131A (ja) 2007-08-09
US20100299765A1 (en) 2010-11-25
KR20070069087A (ko) 2007-07-02
SG155236A1 (en) 2009-09-30
WO2005070011A3 (en) 2005-10-13
JP2024038460A (ja) 2024-03-19
IL267126B (en) 2022-04-01
MX375061B (es) 2025-03-06
US20110117062A1 (en) 2011-05-19
WO2005070011A2 (en) 2005-08-04
AU2021200601A1 (en) 2021-03-04
CN102204930B (zh) 2014-12-03
EP2438815A2 (en) 2012-04-11
US7795025B2 (en) 2010-09-14
EP1708575A2 (en) 2006-10-11
US20150328261A1 (en) 2015-11-19
MX2020009456A (es) 2020-10-12
AU2010249263B2 (en) 2013-04-18
CN104434979A (zh) 2015-03-25
SG10201606441SA (en) 2016-09-29
IL267126A (en) 2019-08-29
CN1968608B (zh) 2011-06-29
EP4248751A2 (en) 2023-09-27
MX343606B (es) 2016-11-11
EP2438816B1 (en) 2019-03-27
EP2438814A3 (en) 2012-10-03
EP2929782A1 (en) 2015-10-14
EP4248752A2 (en) 2023-09-27
CN1968608A (zh) 2007-05-23
ES2721174T3 (es) 2019-07-29
NZ548929A (en) 2010-10-29
EP4248752A3 (en) 2024-01-03
AU2005207042A1 (en) 2005-08-04
US20180064761A1 (en) 2018-03-08
AU2019200513A1 (en) 2019-02-14
JP2022153630A (ja) 2022-10-12
EP1708575A4 (en) 2009-07-01
US9730962B2 (en) 2017-08-15
IL177015B (en) 2019-06-30
AU2016259323B2 (en) 2019-01-31
SG188122A1 (en) 2013-03-28
JP2012148085A (ja) 2012-08-09
EP4269561A2 (en) 2023-11-01
JP2020146575A (ja) 2020-09-17
IL177015A0 (en) 2006-12-10
EP2438816A2 (en) 2012-04-11
US9649340B2 (en) 2017-05-16
US9040770B2 (en) 2015-05-26
US20060018886A1 (en) 2006-01-26
EP2438814A2 (en) 2012-04-11
US20070031386A1 (en) 2007-02-08
JP2015096556A (ja) 2015-05-21
EP2438816A3 (en) 2012-10-03
EP4248751A3 (en) 2023-11-01
AU2016259323A1 (en) 2016-12-01
CN102204930A (zh) 2011-10-05
CA2937099A1 (en) 2005-08-04
AU2005207042B2 (en) 2010-09-09
CA2555370A1 (en) 2005-08-04
JP2019217356A (ja) 2019-12-26
HK1216068A1 (en) 2016-10-14
KR101398356B1 (ko) 2014-05-23
HK1207821A1 (en) 2016-02-12
MX375065B (es) 2025-03-06
KR101258292B1 (ko) 2013-04-25
BRPI0507074A (pt) 2007-06-19
KR20130025953A (ko) 2013-03-12
JP2014079650A (ja) 2014-05-08
KR20120051754A (ko) 2012-05-22
JP2018086274A (ja) 2018-06-07

Similar Documents

Publication Publication Date Title
CA2555370C (en) Improved modalities for the treatment of degenerative diseases of the retina
US20210102164A1 (en) Modalities for the treatment of degenerative diseases of the retina
US20240174978A1 (en) Modalities for the treatment of degenerative diseases of the retina
HK40097391A (en) Improved modalities for the treatment of degenerative diseases of the retina
HK40097392A (en) Improved modalities for the treatment of degenerative diseases of the retina
HK40097393A (en) Improved modalities for the treatment of degenerative diseases of the retina
HK1168994A (en) Improved modalities for the treatment of degenerative diseases of the retina

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20100120